Due to the actions of a 3rd party, our laboratory software is unable to process orders at our normal capacity. This is not a data breach. If this affects your laboratory orders, we will contact you directly. You do not need to call the practice.

Clinical Trials & Research

20248 - PH3 Nirap Abira HRR mCSPC

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Disease Types: Prostate,&nbs

Available at: {clinical_trial_location backspace="7"}20248 - PH3 Nirap Abira HRR mCSPC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}